Appetite medicine becomes everyday healthcare.
Metabolic medicines that change appetite are moving from a niche prescription toward routine care. If access, supply and delivery keep improving, the treatment market grows with them.
Follow in this browser. Revisit Following for evidence updates and call results.
The time-bound call
Fixed at publicationThis basket will outperform the S&P 500 over 90 days.
- Started
- Deadline
- Last updated
How the call is scored
A fixed model basket versus SPYx, each initially quoted from $150 USDC. The original raw token quantities never rebalance. Returns compare their USDC sell quotes with the starting sell quotes. The call succeeds only if the basket's return is strictly higher. Equal returns are a tie. Resolution uses the first complete quote observation started on or after the deadline, within 48 hours. If that window has no valid observation, the result is unresolved. Quotes include route price impact but exclude wallet execution and network costs. These are model returns, not your investment results.
Prices come from live Jupiter quotes and refresh once a day. A price that looks unreliable is skipped rather than guessed.
The deadline only scores the idea. It never sells your holdings and pays no prize. A new version of the thesis starts a new call.
Quote source: Jupiter ↗The argument
Why this idea. Why these businesses.
The FDA extended one of these medicines to reducing the risk of serious heart problems in a defined group of adults with obesity or overweight, which moves it from a weight treatment toward a cardiovascular one. Lilly's published pipeline shows how much development is still aimed at the same field. Our reading: more eligible patients reach treatment as supply, reimbursement and easier forms of delivery improve, and the two companies that lead the field sell into that larger market. Approval, trial results and commercial economics are different facts; the sources establish the first two, not the third.
Inside the basket
- 50%
Eli Lilly
Eli Lilly sells leading metabolic medicines and publishes a deep pipeline in the same field, so it gains if the market widens beyond today's patients.
The tradeoff. Priced for a great deal of growth already, and exposed to price cuts, supply limits and competition. Its other medicines also move the stock.
About this tokenized stock
Underlying: LLY. Issuer: Backed Finance. Backed Finance issues these tokens. The issuer can move tokens out of any wallet (permanent delegate) and can freeze all transfers (pausable). Balances rebase for dividends and splits, so your share count can change without a trade.
Issuer terms (opens in a new tab) - 50%
Novo Nordisk
Novo Nordisk built the category and holds the cardiovascular indication the FDA approved, which is the clearest step from weight loss toward everyday care.
The tradeoff. It has lost ground to competition before, and a Danish company's US-listed token also moves with currency and its own guidance.
About this tokenized stock
Underlying: NVO. Issuer: Backed Finance. Backed Finance issues these tokens. The issuer can move tokens out of any wallet (permanent delegate) and can freeze all transfers (pausable). Balances rebase for dividends and splits, so your share count can change without a trade.
Issuer terms (opens in a new tab)
Why these weights. Equal weights: the claim is that the treatment market grows, not which of the two leaders wins more of it.
The strongest case against
A bigger market can come with lower prices. Governments and insurers push net prices down, many patients stop treatment within a year, competitors and cheaper copies arrive, and a safety finding could change everything. Both companies are already priced for a lot of this growth, so patients can multiply while shareholders earn little.
What would change the thesis?
Across the next two earnings cycles, prescriptions keep rising while net prices and the share of patients who stay on treatment both fall; or a material safety or regulatory setback for the class.
Read the evidence. Make up your mind.
Sources supporting the idea, including the ones that challenge it.
- FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight (opens in a new tab)
U.S. Food and Drug Administration
Extends Wegovy to reducing the risk of cardiovascular death, heart attack and stroke in adults with established heart disease and obesity or overweight. It establishes a specific approved indication in a defined group, not a universal treatment claim or anything about pricing or profit.
- Lilly research and development pipeline (opens in a new tab)
Eli Lilly and Company
The company's own list of medicines in development, showing how much of it targets metabolic disease. A pipeline is intent and trial stage, not approval or future revenue; several programmes will fail.
Updates and version history
An update appends dated evidence to this argument. A new version changes the argument or the allocation itself. Neither one touches a position you already hold.
No updates since publication. When the author adds one, it appears here with its date and its sources — it never changes what is written above.
- Version 1
ec6b73dc57Current
Written by the Thesis team. The team holds no position in these companies or their tokenized shares, and is paid nothing by any of them.
Tracking begins at publication. This thesis has no established performance history. Tokenized stocks carry issuer and market risk.